The Global CINV Existing and Pipeline Drugs Market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to fuel the market growth during the forecast period include the introduction of two new drugs, namely rolapitant and SUSTOL (extended generic granisetron), which in turn will further drive the market, to witness healthy growth in the next few years. Furthermore, the rising number of mergers and acquisitions and the rising focus of the key players on the development of new products are projected to enhance the growth of the market in the next few years. In the last few years, the cases of cancer have been increasing at a tremendous rate in the next few years. Nausea and vomiting are considered as the common side effects that are associated with the chemotherapy of cancer, which is one of the factors that is expected to boost the market growth during the forecast period. 

A significant rise in the R&D activities for cancer and the rising focus on the development of new drugs are some of the key factors that are projected to encourage the growth of the market in the next few years. On the other hand, the low awareness among consumers regarding the availability of new and effective drugs and treatments is projected to restrict the growth of the market in the next few years. Furthermore, an increase in the adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer is most common along with all the types in addition to the existing number of cancer patients. This will further drive the demand for chemotherapy and thereby will accelerate the demand for CINV drugs. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Merck & Co., Inc., GlaxoSmithKline plc, and Novartis International AG (Sandoz), among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global CINV Existing and Pipeline Drugs Market Report by Segment

By Product

• Aloxi

• Zofran Generic

• Kytril Generic

• Emend

• Akynzeo

• SUSTOL

• Rolapitant

Global CINV Existing and Pipeline Drugs Market by Region